This is a phase 1 study for patients with relapsed refractory multiple myeloma. Patients will receive a 15-gram test dose, and a maximum of 3 cycles, each composed of 4 doses of high-dose ascorbic acid (HDAA) and 2 doses of melphalan. This study will enroll 9 patients with relapsed refractory multiple myeloma. The starting dose of ascorbic acid will be 50 grams. Using a 3+3 dose escalation, the dose will potentially increase to 75 grams then 100 grams.
The following criteria is a partial list of reasons why patients may or may not be eligible to participate in this clinical trial. Further evaluation with a medical professional will be required to determine full eligibility.
The following criteria is provided for health care professionals.
Non-secretory participants are eligible provided the participant has > 20% bone marrow plasmacytosis OR multiple (>/= 3) plasmacytomas or lesions on MRI at the time of diagnosis or study enrollment, OR the presence of lesions (>/= 3) on PET/CT scan.
The following is a listing of trial locations that are open and accepting patients.
There are no resources, links or videos to display for this clinical trial.